# Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections

> **NCT07631364** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 360 (estimated)

## Conditions studied

- Neisseria Gonorrhoeae (Ng) Infections

## Interventions

- **DRUG:** Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml)
- **OTHER:** Rectal swab for ESBL-E and microbiota (Eswab)
- **DRUG:** Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml)
- **DRUG:** Ceftriaxone 1 g intramuscular single dose with lidocaine (3,5ml)
- **OTHER:** Rectal, throat, urine/vagina swab (Cobas/Panther and eswab)
- **OTHER:** Blood samples: 1 EDTA (Ethylenediaminetetraacetic acid) (7 ml) and 1dry tube (7 ml)

## Key facts

- **NCT ID:** NCT07631364
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-10
- **Final completion:** 2028-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631364, "Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*